Non-Sterile Compounding Pharmacy Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

Compounding is a growing industry, and the market for non-sterile preparations is expected to grow at a steady rate, reaching a value of $ 4.64 billion in 2024, and $ 6.8 billion by 2035. This growth rate represents a CAGR of 3.54% between 2025 and 2035. The growth of this market is due to several factors, such as the increasing number of chronic diseases, the aging of the population, and the increasing demand for personalized medicine. Also, the automation of pharmaceutical processes and the development of techniques for the preparation of pharmaceutical preparations are important factors that contribute to the increase in the speed and safety of the preparation of medicinal products. Several companies in the non-sterile compounding sector, such as Fagron, PharMEDium Services, and Compounding Pharmacy of America, are involved in strategic initiatives to benefit from this growth. These companies are investing in research and development in order to improve their products and their service. In addition, they are developing strategic alliances to increase the distribution network and improve access to their products. These strategic initiatives will play an important role in the development of the market and in the competition between the companies.

Regional Market Size

Regional Deep Dive

The Non-Sterile Compounding Pharmacy Market is characterized by a growing demand for individualized medicine and a shift toward patient-centric healthcare solutions. The market is characterized by an aging population, an increase in the prevalence of chronic diseases, and an increase in the number of pharmacies. Europe has a robust regulatory framework that supports compounding practices while ensuring patient safety. The Asia-Pacific region is experiencing rapid growth, driven by an increase in access to health care and a growing awareness of individualized medicine. The Middle East and Africa are gradually developing their capacity for compounding, influenced by regulatory changes and improvements in the health care system. Latin America is growing, driven by a growing demand for individualized medicines and a focus on improving health care services.

Europe

• The European Medicines Agency (EMA) has introduced new guidelines for the compounding of medicines, emphasizing the need for quality assurance and patient safety, which is reshaping operational practices in compounding pharmacies across the region.
• Countries like Germany and the UK are seeing a rise in collaborative efforts between compounding pharmacies and hospitals to provide tailored medications, reflecting a trend towards integrated healthcare solutions.

Asia Pacific

• The increasing prevalence of chronic diseases in countries like India and China is driving the demand for customized medications, leading to a surge in the establishment of compounding pharmacies in urban areas.
• Regulatory bodies in Australia are enhancing their frameworks to support the growth of compounding pharmacies, with initiatives aimed at improving the quality and safety of compounded medications.

Latin America

• Brazil is witnessing a rise in compounding pharmacies due to a growing demand for personalized medicine, supported by government initiatives aimed at improving healthcare access and affordability.
• Regulatory changes in countries like Mexico are facilitating the establishment of compounding pharmacies, which are increasingly recognized for their role in providing customized treatments.

North America

• In the United States, the Food and Drug Administration has imposed stricter regulations on the compounding pharmacies, especially after the outbreak of fungal meningitis in 2012. This has led to higher compliance costs but also to higher safety standards in the market.
• Innovations in technology, such as the use of automated compounding devices, are being adopted by pharmacies like PCCA (Professional Compounding Centers of America) to enhance accuracy and efficiency in medication preparation.

Middle East And Africa

• In the UAE, the Ministry of Health and Prevention has launched initiatives to regulate and promote the practice of compounding pharmacies, which is expected to enhance the quality of healthcare services in the region.
• The growing trend of medical tourism in countries like Turkey is leading to an increased demand for personalized medications, prompting local compounding pharmacies to expand their offerings.

Did You Know?

“Did you know that nearly 40% of all prescriptions in the U.S. are for compounded medications, highlighting the significant role of compounding pharmacies in the healthcare system?” — American Pharmacists Association

Segmental Market Size

The Non-Sterile Compounding Pharmacy Market plays a key role in providing medicines according to the needs of individual patients and is currently experiencing a steady growth. The market is mainly driven by the rising prevalence of chronic diseases, which require individual treatment, and the rising awareness of the benefits of compounded drugs among both patients and health care professionals. The favourable regulations, such as the United States' Drug Quality and Security Act, also promote the development of the market. The market is currently in a stage of implementation, with players such as Walgreens and CVS Health deploying non-sterile compounding services across different geographies. The main applications are pain management, hormone therapy, and child preparations, where individual dosages are required. The increasing trend towards patient-oriented care and the development of personalized medicine is expected to accelerate the growth of the market. Also, the development of compounding technology, such as the use of automatic equipment and formulation software, will have a positive impact on the development of this market.

Future Outlook

The non-sterile compounding market will grow steadily from 2024 to 2035, with a projected market growth of 3.54%. This growth is based on the growing demand for individualization of pharmaceuticals, which is in turn due to the increased demand for individualization of pharmaceuticals from both the patient and the doctor. As the population ages and the number of chronic illnesses increases, the need for individualized pharmaceuticals will grow. The penetration of the non-sterile compounding market is expected to increase to more than 20% in certain therapeutic areas by 2035, according to the most credible market research companies and associations. The integration of automation and digital health solutions into the process of non-sterile compounding is expected to increase efficiency and improve the safety of the process. Moreover, the regulatory framework is expected to encourage new entrants and increase confidence in the industry. Telepharmacies and the emergence of patient-oriented care models will also play a major role in shaping the market. As the market evolves, it will provide opportunities for innovation and growth over the next ten years.